Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
10/2009
10/29/2009US20090269321 Immune Function Modulating Agents
10/29/2009US20090269307 Edible Product Containing Ginseng Polysaccharides and Beneficial Bacteria
10/29/2009US20090269302 Human antibodies that bind human il-12 and methods for producing
10/29/2009US20090269285 Diagnostic And Therapeutic Epitope, And Transgenic Plant
10/29/2009DE102008020387A1 Use of pharmaceutical formulation comprising matrix e.g. polysaccharides cellulose and dextran, with protein adsorptive properties, for the prevention or alleviation of symptoms by volatile body sensitizer, infectious or toxic impurities
10/29/2009DE102008019916A1 Use of proteasome inhibitors e.g. for the elimination of durable plasma cells, and for treating diseases that are associated with pathogenic antibodies, e.g. systemic lupus erythematosus, autoimmune hemolytic anemia and immune thrombopenia
10/29/2009CA2722255A1 Inhibitors of ikk-.beta. serine-threonine protein kinase
10/29/2009CA2722184A1 Regulatory b cells and their uses
10/29/2009CA2722173A1 Methods of identifying anti-inflammatory compounds
10/29/2009CA2722082A1 Fc receptor binding proteins
10/29/2009CA2722065A1 Use of deuterium oxide as an elastase inhibitor
10/29/2009CA2722041A1 Novel five-membered ring compound
10/29/2009CA2722007A1 Five-membered ring compound
10/29/2009CA2721920A1 Method of utilization of combination of benzophenone derivative or salt thereof and immunosuppressing agent, and pharmaceutical composition comprising these components
10/29/2009CA2721870A1 Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents
10/29/2009CA2713165A1 Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
10/28/2009EP2112166A2 Human monoclonal antibodies to CTLA-4
10/28/2009EP2112165A2 Methods and compositions for the treatment of glomerulonephritis and other inflammatory diseases
10/28/2009EP2112140A1 Chinazolin derivatives, medicine containing these compounds, application thereof and method for their production
10/28/2009EP2111861A1 Compositions of phosphodiesterase type IV inhibitors
10/28/2009EP2111230A2 Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
10/28/2009EP2111228A2 Vegf pathway blockade
10/28/2009EP1899378B1 Il-1 beta binding antibodies and fragments thereof
10/28/2009EP1633717B1 P2x7 receptor antagonists and their use
10/28/2009EP1503800B1 Treatment and prevention of tissue damage associated with increased c-reactive protein production
10/28/2009EP1497438B1 Means and methods for the production of adenovirus vectors
10/28/2009EP1474120B1 Antibody having a t-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
10/28/2009EP1408967B1 PHARMACEUTICAL COMPOSITIONS BASED ON Tiotropium, Ciclesonide AND a BETAMIMETIC AGENT FOR THE TREATMENT OF INFLAMMATORY AND/OR OBSTRUCTIVE RESPIRATORY TRACT DISEASES
10/28/2009EP1404323B1 Use of methylnaltrexone to treat immune suppression
10/28/2009EP1379504B1 Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors
10/28/2009EP1272168B2 Small organic molecule regulators of cell proliferation
10/28/2009EP1181047B2 Composition comprising alkaline sphingomyelinase of bacterial origin for use as a dietetic preparation, food supplement or pharmaceutical product
10/28/2009EP1150666B1 Gm-csf for the treatment of crohn's disease
10/28/2009EP1128731B1 Compositions of restricted cells capable of rapid growth which produce proliferation suppressive materials, and uses thereof
10/28/2009EP1098908B1 Anti-ccr2 antibodies and methods of use therefor
10/28/2009EP1071758B1 Porcine adenovirus vector
10/28/2009CN101568540A Tricyclic heteroaryl compounds useful as inhibitors of janus kinase
10/28/2009CN101564464A Chinese medicament for adjusting organism immunity of tumor patients
10/28/2009CN101564425A Traditional Chinese medicine composition for curing allergic rhinitis
10/28/2009CN101564415A Chinese medicine microemulsion preparation with enhanced percutaneous permeability and preparation method thereof
10/28/2009CN101564396A Two chamber type nose spraying agent for treating allergic rhinitis
10/28/2009CN101564180A Walnut total nutriment and soft capsule and health products containing same
10/28/2009CN100554430C Recombinant plasmids containing B cell activation factor gene promoters with different lengths and their preparation method and application
10/28/2009CN100554326C Immune polysaccharide of rhizome of manyflower solomonseal, composition and application
10/28/2009CN100553647C Method for preparing extractive of purple daisy
10/28/2009CN100553646C Use of probiotic lactic acid bacteria for balancing the skin's immune system
10/28/2009CN100553636C Method of using diketopiperazines and composition containing them
10/28/2009CN100553623C Chinese caterpillar fungus formulation preparation method
10/28/2009CN100553502C Health-care cigarettes
10/27/2009US7608750 Nonhuman model animal unresponsive to immunopotentiating synthetic compound
10/27/2009US7608683 Human leukocyte antigen pan DR-binding peptides for use in the treatment of infections, inflammatory, autoimmune and cancer diseases; has heat shock protein that is capable of binding to MHC class II molecules
10/27/2009US7608638 Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
10/27/2009US7608634 Substituted pyrrolines as kinase inhibitors
10/27/2009US7608628 Alkylsulphonamide quinolines
10/27/2009US7608627 6-azaindole compound
10/27/2009US7608577 Peptidyl ketones as inhibitors of DPIV
10/27/2009US7608452 Polynucleotides encoding cytokine receptor zcytor19
10/27/2009US7608422 Gene therapy; vaccines; inducing antibodies and/or cytotoxic or helper T lymphocytes
10/27/2009US7608284 Active enamel matrix substance, such as an amelogenin, a processed amelogenin product, or a metabolite can be used in treating conditions in a mammal which present an imbalance in its native immune resposne to external or internal stimuli
10/27/2009US7608274 Therapeutic processes and useful compositions therefor
10/27/2009CA2477019C Use of total coumarins of cnidium fruit in preparing medicaments for treating psoriasis
10/27/2009CA2466724C Benzamide and heteroarylamide as p2x7 receptor antagonists
10/27/2009CA2437006C Aminotriazolopyridine derivatives as adenosine receptor ligands
10/27/2009CA2432713C Aniline derivatives or salts thereof and cytokine production inhibitors containing the same
10/27/2009CA2422210C Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
10/27/2009CA2421826C Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
10/27/2009CA2404514C Novel substance having physiological property, method for producing the same and uses thereof
10/27/2009CA2376355C N-heterocyclic derivatives as nos inhibitors
10/27/2009CA2318694C Antivirals
10/24/2009CA2665510A1 Novel formulations of tumour-associated peptides binding to human leukocyte antigen (hla) class i or ii molecules for vaccines
10/22/2009WO2009129502A2 Immunotherapies employing self-assembling vaccines
10/22/2009WO2009129211A1 Inhibitors of phosphatidylinositol 3-kinase
10/22/2009WO2009128523A1 Immunostimulating agent
10/22/2009WO2009128520A1 Heterocyclic compound having inhibitory activity on p13k
10/22/2009WO2009105355A3 A novel neospora caninum vaccine
10/22/2009WO2009101475A3 Use of glycosylceramides for enhancing the immune response to antigens
10/22/2009WO2009094457A3 Substituted benzhydrylethers
10/22/2009WO2009046827A3 Use of growth hormone-releasing factor and/or mage-3 antigen (271-279) as therapeutic agents
10/22/2009WO2009043518A3 Use of a combination of cart peptides as a therapeutic agent
10/22/2009WO2009040050A3 Use of calcitonin as anti-angiogenic agent
10/22/2009WO2009040048A3 Use of the c-reactive peptide as a therapeutic agent
10/22/2009WO2009040036A3 Use of a galanin peptide as a therapeutic agent
10/22/2009WO2009039982A3 Use of gip alone or in combination with dynorphin b as a therapeutic agent
10/22/2009WO2009039972A3 Use of muramyl dipeptide (mdp) as a therapeutic agent
10/22/2009WO2009039508A9 Preferential killing of cancer cells and activated human t cells using zno nanoparticles
10/22/2009WO2009033810A3 Use of antioxidant peptide a (phckrm) and aplha-casein (90-96) as therapeutic agents in eg the treatment of hiv infection
10/22/2009US20090264515 Polynucleotide therapy
10/22/2009US20090264509 Adenoviral vector-based foot-and-mouth disease vaccine
10/22/2009US20090264506 Delivery of polynucleotide agents to the central nervous system
10/22/2009US20090264469 Novel dicarboxylic acid derivatives
10/22/2009US20090264452 2-(Phenylamino)-Pyrimidin-5-Amides As Cannabinoid 2 Receptors Modulators for the Treatment of Immune or Inflammatory Disorders
10/22/2009US20090264424 Vanilloid receptor ligands and their use in treatments
10/22/2009US20090264415 Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
10/22/2009US20090264399 Heterocyclic janus kinase 3 inhibitors
10/22/2009US20090264384 Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
10/22/2009US20090264339 Heterocyclic Compounds
10/22/2009US20090263883 Recombinant Parainfluenza Virus Expression Systems And Vaccines Comprising Heterologous Antigens Derived From Respiratory Syncytial Virus
10/22/2009US20090263784 Three-dimensional structure of prostaglandin d synthase and utilization thereof
10/22/2009US20090263783 Nucleic sequence and deduced protein sequence family with human endogenous retroviral motifs, and their uses
10/22/2009US20090263474 Methods for Treating Autoimmune Diseases in a Subject and In Vitro Diagnostic Assays
1 ... 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 ... 1172